» Articles » PMID: 27123490

DNA Variants in CACNA1C Modify Parkinson Disease Risk Only when Vitamin D Level is Deficient

Overview
Journal Neurol Genet
Date 2016 Apr 29
PMID 27123490
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate the association between the genetic variants in CACNA1C, which encodes the α1 subunit of the L-type voltage-sensitive calcium channel (LVSCC) and Parkinson disease (PD) while accounting for interactions with vitamin D concentration.

Methods: Two independent case-control data sets (478 cases and 431 controls; 482 cases and 412 controls) were used. Joint effects of single nucleotide polymorphisms (SNPs) and SNP-vitamin D interaction were analyzed by comparing models containing vitamin D deficiency, SNP genotypes, SNP-vitamin D interaction, and covariates to a restricted model with only vitamin D deficiency and covariates. Meta-analysis was used to combine the joint effects in the 2 data sets. Analysis was stratified by vitamin D deficiency to demonstrate the pattern of SNP-vitamin D interaction.

Results: Vitamin D deficiency was associated with PD in both data sets (odds ratio [OR] = 1.9-2.7, p ≤ 0.009). SNP rs34621387 demonstrated a significant joint effect (meta-analysis, p = 7.5 × 10(-5); Bonferroni corrected, p = 0.02). The G allele at rs34621387 is associated with PD in vitamin D-deficient individuals in both data sets (OR = 2.0-2.1, confidence interval = 1.3-3.5, p = 0.002) but is not associated with PD in vitamin D-nondeficient individuals (p > 0.8 in both data sets).

Conclusions: Previous studies suggest that vitamin D deficiency is associated with PD and sustained opening of LVSCC contributes to the selective vulnerability of dopaminergic neurons in PD. Our data demonstrate that the association between genetic variations in CACNA1C and PD depends on vitamin D deficiency, providing one potential mechanism underlying the association between vitamin D deficiency and PD.

Citing Articles

Brain changes in neuroimaging of adult patients with vitamin D deficiency: systematic review protocol.

Porto C, Leao R, Sousa R, Beserra Diniz P, Silva T, Sougey E BMJ Open. 2023; 13(2):e052524.

PMID: 36849215 PMC: 9972426. DOI: 10.1136/bmjopen-2021-052524.


Narcolepsy in Parkinson's disease with insulin resistance.

Chunduri A, Crusio W, Delprato A F1000Res. 2022; 9:1361.

PMID: 34745571 PMC: 8543173. DOI: 10.12688/f1000research.27413.3.


Sporadic Parkinson's Disease Potential Risk Loci Identified in Han Ancestry of Chinese Mainland.

Wang B, Liu X, Xu S, Liu Z, Zhu Y, Zhang X Front Aging Neurosci. 2021; 12:603793.

PMID: 33510632 PMC: 7835639. DOI: 10.3389/fnagi.2020.603793.


Loss of Cav1.2 channels impairs hippocampal theta burst stimulation-induced long-term potentiation.

Sridharan P, Lu Y, Rice R, Pieper A, Rajadhyaksha A Channels (Austin). 2020; 14(1):287-293.

PMID: 32799605 PMC: 7515572. DOI: 10.1080/19336950.2020.1807851.


CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes.

Zhang W, Zhou M, Lu W, Gong J, Gao F, Li Y Theranostics. 2020; 10(7):3000-3021.

PMID: 32194851 PMC: 7053186. DOI: 10.7150/thno.40798.


References
1.
Wang L, Evatt M, Maldonado L, Perry W, Ritchie J, Beecham G . Vitamin D from different sources is inversely associated with Parkinson disease. Mov Disord. 2014; 30(4):560-6. PMC: 4390412. DOI: 10.1002/mds.26117. View

2.
Yoshimizu T, Pan J, Mungenast A, Madison J, Su S, Ketterman J . Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons. Mol Psychiatry. 2015; 20(2):284. DOI: 10.1038/mp.2014.181. View

3.
Erk S, Meyer-Lindenberg A, Schnell K, Opitz von Boberfeld C, Esslinger C, Kirsch P . Brain function in carriers of a genome-wide supported bipolar disorder variant. Arch Gen Psychiatry. 2010; 67(8):803-11. DOI: 10.1001/archgenpsychiatry.2010.94. View

4.
Pasternak B, Svanstrom H, Nielsen N, Fugger L, Melbye M, Hviid A . Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol. 2012; 175(7):627-35. DOI: 10.1093/aje/kwr362. View

5.
Ilijic E, Guzman J, Surmeier D . The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis. 2011; 43(2):364-71. PMC: 3235730. DOI: 10.1016/j.nbd.2011.04.007. View